Kelli Boyd
Faculty Member
Last active: 3/20/2014

Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice - further evaluation.

Alymova IV, Watanabe M, Boyd KL, Chand P, Babu YS, Portner A
Antivir Ther. 2009 14 (7): 891-8

PMID: 19918093 · PMCID: PMC2782883 · DOI:10.3851/IMP1420

BACKGROUND - Human parainfluenza virus type 1 (hPIV-1) causes serious respiratory tract infections, especially in children. This study investigated the efficacy of the novel haemagglutinin-neuraminidase (HN) inhibitor BCX 2798 in the prophylaxis of lethal and the treatment of non-lethal parainfluenza virus infection in mice.

METHODS - In the prophylaxis model, 129x1/SvJ mice were inoculated with a 90% lethal dose of a recombinant Sendai virus, in which the HN gene was replaced with that of hPIV-1 (rSeV[hPIV-1HN]). The mice were intranasally treated either once or for 5 days with 1 or 10 mg/kg/day of BCX 2798, starting 4 h before infection. In the therapeutic model, mice were infected with 100 plaque-forming units of rSeV(hPIV-1HN) per mouse and treated intranasally with 0.1, 1 or 10 mg/kg/day of BCX 2798 for 5 days, starting 24 or 48 h after infection, or for 4 days starting 72 h after infection.

RESULTS - Similar to multiple dosing, a single intranasal prophylaxis with 1 or 10 mg/kg of BCX 2798 protected approximately 40% or 90%, respectively, of mice from death by rSeV(hPIV-1HN) infection. BCX 2798 also significantly reduced virus lung titres (in a dose- and time-dependent manner) and reduced histopathological changes in the airways of non-lethally infected mice at multiple intranasal dosages in the therapeutic model, with the lowest effective dosage being 0.1 mg/kg/day administered 24 h after infection.

CONCLUSIONS - BCX 2798 was effective in the prophylaxis of lethal and in the therapy of non-lethal parainfluenza virus infection in mice, suggesting further consideration of BCX 2798 for clinical trials.

MeSH Terms (16)

Administration, Intranasal Animals Azides Cell Line Dose-Response Relationship, Drug Enzyme Inhibitors Female Hexuronic Acids HN Protein Humans Macaca mulatta Mice Parainfluenza Virus 1, Human Premedication Respirovirus Infections Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: